Phase 3 N=23 Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism
Alcohol Dependence · Schizophrenia
Primary: Number of Drinking Days — 10.7; 7.6 days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=28 Selumetinib in Cancers With BRAF Mutations
Adult Solid Neoplasm
Primary: Objective Response Rate in Patients With Cancers Other Than Melanoma — 0 percentage of participants
N/A N=48 Behavioral Treatment for Children With Conduct Problems and Callous-Unemotional Traits
Conduct Disorder · Oppositional Defiant Disorder
Primary: Conduct Problems — 0.76; 1.08; 0.41; 0.92 Number of conduct problems per day
Phase 4 N=48 Effects of Intravenous Lidocaine Associated With Magnesium Sulfate on the Cisatracurium-Induced Neuromuscular Block
Neuromuscular Block
Primary: Latency — 139.70; 151.30; 147.80 seconds — p=0.9651
Phase 2 N=48 Pharmacokinetics and Tolerability of Vortioxetine (Lu AA21004) in Child and Adolescent Patients With Depressive or Anxiety Disorder
Depressive Disorder · Anxiety Disorder
Primary: Cmax of Vortioxetine — 4.3; 7.8; 15; 16 ng/mL
Phase 2 N=85 Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 4 or 5 HCV Infection
Chronic Genotype 4 HCV · Chronic Genotype 5 HCV
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 95.5; 90.9; 95.2; 95.0 percentage of participants
Phase 4 N=11,679 SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.
Asthma
Primary: Number of Participants Experiencing an Event in the Composite Safety Endpoint of Serious Asthma Outcomes ( Asthma-related Hospitalization, Asthma-related Endotracheal…
Phase 2 N=62 Phase 2 Study for the Treatment of Superficial Lipomas
Lipoma
Primary: Number of Participants With Adverse Events (AEs) — 12; 13; 14; 12 participants
Phase 2 N=30 Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic Diseases
Chronic Leukemia · Acute Leukemia · Hodgkin's Disease
Primary: Percentage of Patients Experiencing Hemorrhagic Cystitis Post Transplant — 30 percentage of patients
Phase 3 N=209 Safety and Tolerability of Glatiramer Acetate
Relapsing-Remitting Multiple Sclerosis
Primary: Adjusted Mean Estimates for Injection-Related Adverse Event Rate Per Year in the Core Period — 70.403; 35.275 events per year — p=0.0006
Phase 3 N=833 A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 Diabetes
Diabetes · Diabetes Mellitus, Type 2
Primary: Change From Baseline in HbA1c (%) (Analysed by Central Laboratory) — -1.3; -1.2 percentage of glycosylated haemoglobin
Phase 4 N=38 Equivalence of Calcium Acetate Oral Solution and Sevelamer Carbonate Tablets in Hemodialysis Patients
Chronic Kidney Disease
Primary: Serum Phosphorus Levels — 4.6; 4.6 mg/dL
Phase 1 N=30 Afatinib in Subjects With Kidney Dysfunction
Renal Insufficiency
Primary: AUC 0-tz of Afatinib (BIBW 2992) — 948; 952; 776; 634 ng*h/mL
Phase 3 N=471 A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).
Parkinson's Disease
Primary: Percentage of "Off" Time During Waking Hours at End of Study — 23.82; 29.79 percentage — p=<.0001
Phase 2 N=97 Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis · Multiple Sclerosis
Primary: Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), and Discontinuations Due to AEs — 92; 52; 10; 33 participants